Trajectories of Prescription Drug Misuse among US Adults from Ages 18 to 50 Years

Importance: US adults born from 1965 to 1996 had high exposure to controlled medications, yet little is known about how this exposure has affected them over time. Prescription drug misuse (PDM) has increased among adults in the past 2 decades, with related increases in emergency department visits, o...

Full description

Bibliographic Details
Main Authors: Evans-Polce, R.J (Author), McCabe, S.E (Author), McCabe, V.V (Author), Schepis, T.S (Author), Schulenberg, J.E (Author), Veliz, P.T (Author), Wilens, T.E (Author)
Format: Article
Language:English
Published: American Medical Association 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 05217nam a2200697Ia 4500
001 10-1001-jamanetworkopen-2021-41995
008 220420s2022 CNT 000 0 und d
020 |a 25743805 (ISSN) 
245 1 0 |a Trajectories of Prescription Drug Misuse among US Adults from Ages 18 to 50 Years 
260 0 |b American Medical Association  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1001/jamanetworkopen.2021.41995 
520 3 |a Importance: US adults born from 1965 to 1996 had high exposure to controlled medications, yet little is known about how this exposure has affected them over time. Prescription drug misuse (PDM) has increased among adults in the past 2 decades, with related increases in emergency department visits, overdoses, and deaths. Objectives: To identify 32-year PDM trajectories involving opioids, stimulants, and sedatives or tranquilizers and to examine associations between these PDM trajectories and substance use disorder (SUD) symptoms in adulthood as well as between baseline characteristics and PDM trajectories. Design, Setting, and Participants: This cohort study included 11 cohorts of adolescents who were followed up longitudinally from age 18 years (study start, 1976-1986) to age 50 years (2008-2018) in the Monitoring the Future (MTF) study, which included a national multistage random sample of US 12th grade students. Baseline surveys (modal age 18) were self-administered in classrooms. Ten follow-ups were conducted by mail. Data analysis was conducted from December 2020 to October 2021. Main Outcomes and Measures: Sociodemographic variables were measured at baseline. PDM and SUD symptoms were measured at baseline and every follow-up. Latent profile analysis (LPA) was used to create PDM trajectory profiles. Associations between these PDM trajectories, SUD symptoms, and baseline sociodemographic characteristics were examined. Results: The sample of 26575 individuals was 50.8% (95% CI, 50.2%-51.4%) female and 79.3% (95% CI, 78.8%-79.8%) White. The baseline response rate ranged from 77% to 84%, and the 32-year retention rate was 53%. In adjusting for attrition, 45.7% (95% CI, 44.9%-46.4%) of the respondents reported past-year PDM at least once during the 32-year reporting period. Among those who reported PDM, the prevalence of poly-PDM was 40.3% (95% CI, 39.3%-41.3%). Based on LPA, the number of class-specific PDM trajectories ranged from 4 (prescription opioids) to 6 (prescription stimulants). For the class-combined analyses, we identified 8 PDM trajectories consisting of early peak trajectories (eg, age 18 years), later peak trajectories (eg, age 40 years), and a high-risk trajectory (eg, high frequency PDM at multiple ages). All PDM trajectories were associated with increased odds of developing SUD symptoms in middle adulthood, especially the later peak and high-risk trajectories compared with early peak trajectories (eg, peak at age 40 years: adjusted odds ratio [aOR], 5.17; 95% CI, 3.97-6.73; high-risk: aOR, 12.41; 95% CI, 8.47-18.24). Baseline characteristics associated with a high-risk trajectory were binge drinking (aOR, 1.69; 95% CI, 1.13-2.54), cigarette smoking (aOR, 2.30; 95% CI, 1.60-3.29), and marijuana use (aOR, 3.78; 95% CI, 2.38-6.01). More recent cohorts (eg, 1985-1986) had a higher risk of belonging to later peak PDM trajectories (ages 40 and 45 years) than the 1976-1978 cohort (age 40 years peak: aOR, 2.49; 95% CI, 1.69-3.68). Conclusions and Relevance: In this cohort study, adults with later peak PDM trajectories were at increased risk of SUD symptoms in middle adulthood. These findings suggest the need to screen for PDM and SUD from adolescence through middle adulthood.. © 2022 American Medical Association. All rights reserved. 
650 0 4 |a adolescent 
650 0 4 |a Adolescent 
650 0 4 |a adult 
650 0 4 |a Adult 
650 0 4 |a adulthood 
650 0 4 |a anonymised data 
650 0 4 |a Article 
650 0 4 |a binge drinking 
650 0 4 |a cannabis use 
650 0 4 |a Caucasian 
650 0 4 |a central stimulant agent 
650 0 4 |a cigarette smoking 
650 0 4 |a cohort analysis 
650 0 4 |a Cohort Studies 
650 0 4 |a controlled study 
650 0 4 |a demography 
650 0 4 |a drug dependence 
650 0 4 |a female 
650 0 4 |a follow up 
650 0 4 |a high risk population 
650 0 4 |a high school 
650 0 4 |a human 
650 0 4 |a human tissue 
650 0 4 |a Humans 
650 0 4 |a longitudinal study 
650 0 4 |a major clinical study 
650 0 4 |a male 
650 0 4 |a middle aged 
650 0 4 |a Middle Aged 
650 0 4 |a opiate 
650 0 4 |a parent 
650 0 4 |a prescription 
650 0 4 |a prescription drug misuse 
650 0 4 |a Prescription Drug Misuse 
650 0 4 |a prevalence 
650 0 4 |a sedative agent 
650 0 4 |a tranquilizer 
650 0 4 |a United States 
650 0 4 |a United States 
650 0 4 |a young adult 
650 0 4 |a Young Adult 
700 1 0 |a Evans-Polce, R.J.  |e author 
700 1 0 |a McCabe, S.E.  |e author 
700 1 0 |a McCabe, V.V.  |e author 
700 1 0 |a Schepis, T.S.  |e author 
700 1 0 |a Schulenberg, J.E.  |e author 
700 1 0 |a Veliz, P.T.  |e author 
700 1 0 |a Wilens, T.E.  |e author 
773 |t JAMA Network Open